Anti-TNF biosimilars in Crohn's Disease: A patient-centric interdisciplinary approach.

Anti-TNF biosimilars in Crohn's Disease: A patient-centric interdisciplinary approach. Expert Rev Gastroenterol Hepatol. 2019 Jul 19;: Authors: Laurent PB, Silvio D, Fraser C, Raja A, Kay G, Burkhard P, Taegyun K Abstract Introduction: The purpose of this review is to highlight the role of biosimilars in early treatment in IBD and introduce ways to facilitate a patient-centric switching process through multidisciplinary approach. Areas covered: We summarize existing scientific literature related to the role of biosimilars in inflammatory bowel disease in terms of early treatment and cost-saving and implementing switching process. Expert opinion: Use of anti-TNF biosimilars in patients has the potential for large drug-acquisition cost-saving, which can be reinvested into early treatment. Managed switched programs for adalimumab can add further benefits in the future. PMID: 31322440 [PubMed - as supplied by publisher]
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research